A Call for a New Paradigm for Diabetes Care in the Era of Sodium –Glucose Cotransporter 2 Inhibitors (SGLT2i)
This article is based on previously conducted studies and the authors disclose their roles in relevant trials in the Acknowledgements.
Source: Cardiology and Therapy - Category: Cardiology Source Type: research
More News: Canagliflozin | Cardiology | Cardiovascular | Dapagliflozin | Diabetes | Empagliflozin | Endocrinology | Food and Drug Administration (FDA) | Forxiga | Heart | Heart Attack | Heart Failure | Invokana | Jardiance | Primary Care | Sodium | Stroke | Study | Urology & Nephrology